|
1
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fodde R, Smits R and Clevers H: APC,
signal transduction and genetic instability in colon cancer. Nat
Rev Cancer. 1:55–67. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Levine AJ, Jenkins NA and Copeland NG: The
roles of initiating truncal mutations in human cancers: The order
of mutations and tumor cell type matters. Cancer Cell. 35:10–15.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fodde R, Edelman W, Yang K, Van Leuwen C,
Carlson C, Renault B, Breukel C, Alt E, Lipkin M, Khan PM, et al: A
targeted chain termination mutation in the mouse Apc gene results
in multiple intestinal tumors. Proc Natl Acad Sci USA.
91:8969–8973. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Su LK, Kinzler KW, Vogelstein B,
Preisinger AC, Moser AR, Luongo C, Gould KA and Dove WF: Multiple
intestinal neoplasia caused by a mutation in the murine homolog of
the APC gene. Science. 256:668–670. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Beazer-Barclay Y, Levy DB, Moser AR, Dove
WF, Hamilton SR, Vogelstein B and Kinzler KW: Sulindac suppresses
tumorigenesis in in the min mouse. Carcinogenesis. 17:1757–1760.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jacoby RF, Seibert K, Cole CE, Kelloff G
and Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent
preventive and therapeutic agent in the min mouse model of
adenomatous polyposis. Cancer Res. 60:5040–5044. 2000.PubMed/NCBI
|
|
8
|
Boolbol SK, Dannenberg AL, Chadburn A,
Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin
ML, DeCosse JJ and Bertagnolli MM: Cyclooxygenase-2 overexpression
and tumor formation are blocked by sulindac in a murine model of
familial adenomatous polyposis. Cancer Res. 56:2556–2560.
1996.PubMed/NCBI
|
|
9
|
Ju J, Hong J, Zhou JN, Pan Z, Bose M, Liao
J, Yang GY, Liu YY, Hou Z, Lin Y, et al: Inhibition of intestinal
tumorigenesis in Apcmin/+ mice by (−)-epigallocatechin-3-gallate,
the major catechin in green tea. Cancer Res. 65:10623–10631. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Perkins S, Verschoyle RD, Hill K, Parveen
I, Threadgil MD, Sharma RA, Williams ML, Steward WP and Gescher AJ:
Chemopreventive efficacy and pharmacokinetics of curcumin in the
min/+ mouse, a model of familial adenomatous polyposis. Cancer Epid
Biomark Prev. 11:535–540. 2002.
|
|
11
|
Giardiello FM, Hamilton SR, Krush AJ,
Piantadisis S, Hylind LM, Cellano P, Brooker SV, Robinson CR and
Offerhans GL: Treatment of colonic and rectal adenomas with
sulindac in familial adenomatous polyposis. N Engl J Med.
328:1313–1316. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Steinbeck G, Lynch PM, Phillips RK,
Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y,
Fujimura T, et al: The effect of celecoxib, a cyclooxygenase-2
inhibitor, in familial adenomatous polyposis. N Engl J Med.
342:1946–1952. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gupta RA and Dubois RN: Colorectal cancer
prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev
Cancer. 1:11–21. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
JacobyR F, Cole CE, Tutsch F, Newton MA,
Kelloff G, Hawk ET and Lubet RA: Chemopreventive efficacy of
combined piroxicam and difluoromethylornithine treatment of Apc
mutant min mouse adenomas, and selective toxicity against Apc
mutant embryos. Cancer Res. 60:1864–1870. 2000.PubMed/NCBI
|
|
15
|
Swamy MV, Patlolla JMR, Steele VE,
Kopelovich L, Reddy BS and Rao CV: Chemoprevention of familial
adenomatous polyposis by low doses of atorvastatin and celecoxib
given individually and in combination to APCMin mice. Cancer Res.
66:7370–7377. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meyskens FL Jr, McLaren CE, Pelot D,
Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ,
Kidao J, McCracken J, et al: Difluoromethylornithine plus sulindac
for the prevention of sporadic colorectal adenomas: A randomized
placebo-controlled, double-blind trial. Cancer Prev Res (Phila).
1:32–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dean M, Fojo T and Bates S: Tumor stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Telang NT, Li G and Katdare M: Prevention
of early-onset familial/hereditary colon cancer: New models and
mechanistic biomarkers (review). Int J Oncol. 28:1523–1529.
2006.PubMed/NCBI
|
|
19
|
Telang N and Katdare M: Combinatorial
prevention of carcinogenic risk in a model for familial colon
cancer. Oncol Rep. 17:909–914. 2007.PubMed/NCBI
|
|
20
|
Tanei T, Morimoto K, Shimazu K, Kim SJ,
Tanji Y, Taguchi T, Tamaki Y and Noguchi S: Association of breast
cancer stem cells identified by aldehyde dehydrogenase 1 expression
with resistance to sequential Paclitaxel and epirubicin-based
chemotherapy for breast cancers. Clin Cancer Res. 15:4234–4241.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Van Phuc P, Nhan PL, Nhung TH, Tam NT,
Hoang NM, Tue VG, Thuy DT and Ngoc PK: Downregulation of CD44
reduces doxorubicin resistance of CD44CD24 breast cancer cells.
Onco Targets Ther. 4:71–78. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang F, Song C, Ma Y, Tang L, Xu Y and
Wang H: Effect of fibroblasts on breast cancer cell mammosphere
formation and regulation of stem cell-related gene expression. Int
J Mol Med. 28:365–371. 2011.PubMed/NCBI
|
|
23
|
Dalebra P, Dylla SJ, Park IK, Luiu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simone DM, et al: Phenotypic
characterization of human colorectal cancer stem cells. Proc Natl
Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
O'Brien CA, Polett A, Gallinger S and Dick
JE: A human colon cancer cell capable of initiating tumour growth
in immunodeficient mice. Nature. 445:106–110. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ricci-Vitiani L, Lombardi DG, Pillozi E,
Biffoni M, Todaro M, Peschele C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Crespo M, Villar E, Tsai SY, Chang K, Amin
S, Srinivasan T, Zhang T, Pipalia NH, Chen HJ, Witherspoon M, et
al: Colonic organoids derived from human induced pluripotent stem
cells for modeling colorectal cancer and drug testing. Nat Med.
23:878–884. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takahashi K, Tanabe K, Ohnuli M, Narita M,
Ishsaka T, Tomoda K and Yamanaka S: Induction of pluripotent stem
cells from adult human fibroblasts by defined factors. Cell.
131:861–872. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park IH, Zhao R, West JA, Yabuuchi A, Huo
H, Ince TA, Lerou PH, Lensch MW and Daley GQ: Reprogramming of
human somatic cells to pluripotency with defined factors. Nature.
451:141–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu J, Hu K, Smuga-Otto K, Tian S, Stuart
R, Slukvin II and Thompson JA: Human induced pluripotent stem cells
free of vector and transgene sequences. Science. 324:797–801. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Telang N: Anti-inflammatory drug
resistance selects putative cancer stem cells in a cellular model
for genetically predisposed colon cancer. Oncol Letts. 15:642–648.
2018.
|
|
31
|
Katdare M, Kopelovich L and Telang N:
Efficacy of chemopreventive agents for growth inhibition of Apc
[+/−] 1638NCOL colonic epithelial cells. Int J Mol Med. 10:427–432.
2002.PubMed/NCBI
|
|
32
|
Telang N and Katdare M: Novel cell culture
model for prevention of carcinogenic risk in familial adenomatous
polyposis syndrome. Oncol Rep. 21:1017–1021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Telang NT and Williams GM:
Carcinogen-induced DNA damage and cellular alterations in F344 rat
colon organ cultures. J Natl Cancer Inst. 68:1015–1022.
1982.PubMed/NCBI
|
|
34
|
Anastas JN and Moon RT: WNT signalling
pathways as therapeutic targets in cancer. Nat Rev Cancer.
13:11–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang C, Xie CJ, Guo J, Manning HC, Gore JC
and Gou N: Evaluation of CD44 and CD133 as cancer stem cell markers
for colorectal cancer. Oncol Rep. 28:1301–1308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou JY, Chen M, Ma I, Wang X, Chen YG and
Lui SL: Role of CD44(high)/CD133(high) HCT-116 cells in the
tumorigenesis of colon cancer. Oncotarget. 7:7657–7666. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zeilstra J, Joosten SP, Dokter M, Verwiel
E, Spaargaren M and Pals ST: Deletion of the WNT target and cancer
stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal
tumorigenesis. Cancer Res. 68:3655–3661. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moser AR, Pitot HC and Dove WF: A dominant
mutation that predisposes to multiple intestinal neoplasia in the
mouse. Science. 247:322–324. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sinicrope FA, Velamala PR, Song LMWK,
Viggiano TR, Bruining DH, Rajan E, Gostout CJ, Kraichely RE, Buttar
NS, Schroeder KW, et al: Efficacy of difluoromethylornithine and
aspirin for treatment of adenomas and aberrant crypt foci in
patients with prior advanced colorectal neoplasms. Cancer Prev Res
(Phila). 12:821–830. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou W, Kallifaditis G, Baumann B, Rausch
V, Mattern J, Galdkich J, Geiss N, Moldenhaur G, Wirth T, Büchler
MW, et al: Dietary polyphenol quercetin targets pancreatic cancer
stem cells. Int J Oncol. 37:551–561. 2010.PubMed/NCBI
|
|
41
|
Rausch V, Liu I, Kallifatidis G, Baumann
B, Mattern J, Gladkich I, Wirth T, Schemmer P, Buchler MW, Zöller
M, et al: Synergistic activity of sorafenib and sulforaphane
abolishes pancreatic cancer stem cell characteristics. Cancer Res.
70:5004–5013. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kallifatidis G, Labsch S, Rausch V,
Mattern J, Gladkich J, Moldenhauer G, Büchler MW, Salnikov AV and
Herr I: Sulforaphane increases drug-mediated cytotoxicity toward
cancer stem-like cells of pancreas and prostate. Mol Ther.
19:188–195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nguyen PH, Giraud J, Staedel C,
Chambonnier L, Dubus P, Chevret E, Bœuf H, Gautherea X, Rousseau B,
Fevre M, et al: All-trans retinoic acid targets gastric cancer stem
cells and inhibits patient-derived gastric carcinoma tumor growth.
Oncogene. 35:5619–5628. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Castro NP, Rangel MC, Merchant AS,
MacKnnon G, Cuttitta F, Salomon DA and Kim YS: Sulforaphane
suppresses the growth of triple-negative breast cancer stem-like
cells in vitro and in vivo. Cancer Prev Res (Phila). 12:147–158.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim SH and Singh SV: Role of Krüppel-like
factor 4-p21CIP1 axis in breast cancer stem-like cell
inhibition by benzyl isothiocyanate. Cancer Prev Res (Phila).
12:125–134. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Telang N: Stem cell targeted therapeutic
approaches for molecular subtypes of clinical breast cancer
(Review). World Acad Sci J. 1:20–24. 2019. View Article : Google Scholar
|
|
47
|
Telang N: Targeting drug resistance stem
cells in a human epidermal growth factor receptor-2-enriched breast
cancer model. World Acad Sci J. 1:86–91. 2019.
|
|
48
|
Matano M, date S, Shimokava M, Takano A,
Fuji M, Ohta Y, Watanabe T, Konai T and Sato M: Modeling colorectal
cancer using CRISPR-Cas9-mediated engineering of human intestinal
organoids. Nat Med. 21:256–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li Y, Li X, Qu J, Luo D and Hu Z: Cas9
mediated correction of β-catenin mutation and restoring the
expression of protein phosphorylation in colon cancer HCT-116 cells
decrease cell proliferation in vitro and hamper tumor growth in
mice in vivo. Onco Targets Ther. 13:17–29. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Drost J, van Jaarsveld RH, Ponsioen B,
Zimberlin C, van Boxtel R, Buijs A, Sachs N, Overmeer RM, Offerhaus
GJ, Begthel H, et al: Sequential cancer mutations in cultured human
intestinal stem cells. Nature. 521:43–47. 2015. View Article : Google Scholar : PubMed/NCBI
|
